New application

Article

The first femtosecond-only method of laser vision correction from Carl Zeiss Meditec is now available for sale outside the United States.

The first femtosecond-only method of laser vision correction from Carl Zeiss Meditec is now available for sale outside the United States. ReLEx is a new application that allows ophthalmic surgeons to perform a variety of complete laser vision correction procedures using only the VisuMax Femtosecond laser.

ReLEx allows for very small flap sizes, typically just 0.5 to 1 mm larger in diameter than the optical zone. Furthermore, ReLEx provides an easier and much faster workflow for the surgeon as the entire procedure can be performed using a single laser. To date, ReLEx procedures have been performed on more than 1000 eyes at a variety of locations outside the US.

In a recent study in which the ReLEx Femtosecond Lamellar Extraction (FLEX) method was performed by Professor Osama Ibrahim, MD at ALEX Laser Center in Alexandria, Egypt, ReLEx compared favourably to LASIK in terms of efficacy, stability, and safety. 102 eyes (71 female eyes and 31 male eyes) with myopia or myopic astigmatism with a spherical equivalent of -5.07 D ± 2.77 D were treated. At the 3-month follow-up, 95% of eyes treated were within ± 1.00 D and 76% of eyes were within ± 0.50 D of intended correction. Mean spherical equivalent was -0.17 D ± 0.64 D at 1 month. Stability was seen at one week postoperatively. A total of 85% of eyes achieved an uncorrected distance visual acuity (UDVA) of 20/20 or greater at 1 month and 84% of eyes showed UDVA of 20/25 or better at day one.

No change in corrected distance visual acuity (CDVA) was reported in 69% of eyes however, a gain of one or more lines was achieved in 9% of eyes. A loss of more than 2 lines occurred in 2 percent at 1 month.

“Until now, laser vision correction has been a two-part process in which the patient must be moved from one platform to another, ” said Professor Osama Ibrahim. “With ReLEx using the VisuMax Femtosecond Laser, I achieved consistently excellent visual outcomes while enhancing patient comfort, both of which are essential to achieve a high level of satisfaction in today’s elective surgery environment. ”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.